• New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment 

      Dastiridou, A.; Kalogeropoulos, C.; Brazitikos, P.; Symeonidis, C.; Androudi, S. (2012)
      Current treatment guidelines for chronic ocular inflammatory disease recommend the use of steroid-sparing agents. The development of conventional immunomodulatory agents has largely changed the visual outcome in these ...
    • Orbital cellulitis 

      Tsirouki T., Dastiridou A.I., Ibánez flores N., Cerpa J.C., Moschos M.M., Brazitikos P., Androudi S. (2018)
      Orbital cellulitis (OC) is an inflammatory process that involves the tissues located posterior to the orbital septum within the bony orbit, but the term generally is used to describe infectious inflammation. It manifests ...
    • Rituximab Treatment for Persistent Scleritis Associated with Rheumatoid Arthritis 

      Iaccheri, B.; Androudi, S.; Bocci, E. B.; Gerli, R.; Cagini, C.; Fiore, T. (2010)
      Purpose: To report a clinical case of a patient with severe scleritis associated with rheumatoid arthritis (RA) refractive to conventional treatment that was treated effectively with rituximab. Methods and Results: A ...